Cytomed Therapeutics Ltd (GDTC)

Is Cytomed Therapeutics Ltd (GDTC) A Buy Now?

According to our latest analysis, GDTC could be considered a Strong Sell, with 17 technical analysis indicators signaling 1 Buy signals, 11 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on GDTC, as trading bearish markets can be challenging and may result in losses.

1. RSI (Relative Strength Index): The RSI(14) value of 45.52 indicates that GDTC is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
2. STOCH (Stochastic Oscillator): The STOCH value of 65.47 indicates that GDTC is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
3. STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 13.06 indicates that GDTC is oversold. This suggests that GDTC price is at or near the lowest level relative to its recent price history.
4. ADX (Average Directional Index): The ADX value of 19.48 suggests that there may be some movement in price, but it lacks strength or conviction.
5. CCI (Commodity Channel Index): A CCI(14) value of -78.07 indicates that GDTC is still oversold but not to an extreme extent.

Long-term GDTC price forecast for 2026, 2030, 2035, 2040, 2045 and 2050

Based on our analysis about Cytomed Therapeutics Ltd financial reports and earnings history, Cytomed Therapeutics Ltd (GDTC) stock could reach $1.91 by 2030, $5.51 by 2040 and $13.50 by 2050. See the projected annual prices until 2050 of the Cytomed Therapeutics Ltd stock below:

• Cytomed Therapeutics Ltd (GDTC) is expected to reach an average price of $3.67 in 2035, with a high prediction of $4.27 and a low estimate of $2.03. This indicates an +321.50% change from the last recorded price of $0.87.
• Cytomed Therapeutics Ltd (GDTC) stock is projected to chart a bullish course in 2040, with an average price target of $3.43, representing an +294.24% change from its current level. The forecast ranges from a conservative $3.08 to a sky-high $5.51.
• Our analysts predict Cytomed Therapeutics Ltd (GDTC) to change +385.30% by 2045, soaring from $3.64 to an average price of $4.22, potentially reaching $4.75. While $3.64 is the low estimate, the potential upside is significant.
• Cytomed Therapeutics Ltd (GDTC) stock is expected to climb by 2050, reaching an average of $13.96, a +1,505% change from its current level. However, a wide range of estimates exists, with high and low targets of $13.50 and $3.11, respectively, highlighting the market's uncertainty.

Cytomed Therapeutics Ltd Stock (GDTC) Year by Year Forecast